|
|
- 2016
microRNA-451在弥漫性大B细胞淋巴瘤患者血浆中的表达及意义
|
Abstract:
摘要：目的 探讨microRNA-451(miR-451)在弥漫性大B细胞淋巴瘤(diffuse large B lymphoma, DLBCL)患者血浆中的表达水平及其临床意义。方法 利用逆转录聚合酶链反应(reverse transcription polymerase chain reaction, RT-PCR)方法检测27例DLBCL患者和27例健康体检者血浆中miR-451的表达水平，并统计分析DLBCL患者血浆中miR-451表达水平与临床病理参数之间的关系。结果 miR-451在DLBCL患者血浆中表达水平明显低于正常对照组[(0.41±0.15)vs.(0.64±0.21)]，二者差异具有统计学意义(P<0.01)；DLBCL患者血浆中miR-451表达水平在不同性别、年龄、血清LDH水平及原发部位之间差异无统计学意义(P>0.05)，而与Ann Arbor分期及IPI评分明显相关(P<0.05)。结论 DLBCL患者血浆中miR-451表达水平降低，可能参与了DLBCL的病理过程。
ABSTRACT: Objective To explore the expression level and clinical significance of microRNA-451 (miR-451) in the plasma of patients with diffuse large B lymphoma (DLBCL). Methods We enrolled 27 patients with DLBCL and 27 healthy controls for the study. The plasma level of miR-451 was detected by reverse transcription polymerase chain reaction (RT-PCR). Then we analyzed the relationship between the plasma level of miR-451 and pathological characteristics of DLBCL. Results The plasma level of miR-451 in the patients with DLBCL was significantly lower than in healthy controls [(0.41±0.15) vs. (0.64±0.21)] (P<0.01). However, the plasma level of miR-451 was not significantly correlated with the patients？？ gender, age, serum LDH level or primary site (P>0.05), but with Ann Arbor tumor stage and IPI score (P<0.05). Conclusion The plasma level of miR-451 decreases in patients with DLBCL, which indicates that miR-451 may participate in the pathology of DLBCL
| [1] | LAFARO KJ, DEMIRJIAN AN, PAWLIK TM. Epidemiology of hepatocellular carcinoma[J]. Surg Oncol Clin N Am, 2015, 24(1):1-17. |
| [2] | BANDDRES E, BITARTE N, ARIAS F, et al. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells[J]. Clin Cancer Res, 2009, 15(7):2281-2290. |
| [3] | 中华医学会血液学分会、中国抗癌协会淋巴瘤专业委员会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J]. 中华血液学杂志, 2013, 34(9):816-819. |
| [4] | TROPPAN K, WENZL K, DEUTSCH A, et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy[J]. Anticancer Res, 2014, 34(2):557-564. |
| [5] | TAKE Y, OHNISHI N, KISAKA M, et al. Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas[J]. Springerplus, 2014, 3:288. |
| [6] | CHAN WJ. Pathogenesis of diffuse large B cell lymphoma[J]. Int J Hematol, 2010, 92(2):219-230. |
| [7] | J？？RGENSEN LK, POULSEN M？h, LAURSEN MB, et al. MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma―a systematic review[J]. Dan Med J, 2015, 62(5):A5048. |
| [8] | SHEPSHELOVICH D, RAM R, UZIEL O, et al. MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma[J]. Leuk Res, 2015, 39(6):632-637. |
| [9] | SONG G, GU L, LI J, et al. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients[J]. Ann Hematol, 2014, 93(10):1735-1743. |
| [10] | JANSSON MD, LUND AH. MicroRNA and cancer[J]. Mol Oncol, 2012, 6(6):590-610. |
| [11] | ZHENG RL, JIANG YJ, WANG X. Role of microRNAs on therapy resistance in non-Hodgkin’s lymphoma[J]. Int J Clin Exp Med, 2014, 7(11):3818-3832. |
| [12] | PAN Y, MENG M, ZHANG G, et al. Oncogenic microRNAs in the genesis of leukemia and lymphoma[J]. Curr Pharm Des, 2014, 20(33):5260-5267. |
| [13] | PAN X, WANG R, WANG ZX. The potential role of miR-451 in cancer diagnosis, prognosis, and therapy[J]. Mol Cancer Ther, 2013, 12(7):1153-1162. |
| [14] | SU Z, ZHAO J, RONG Z, et al. MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer[J]. Int J Clin Exp Pathol, 2015, 8(8):9154-9160. |
| [15] | ZENG T, PENG L, CHAO C, et al. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT[J]. Int J Clin Exp Pathol, 2014, 7(11):7653-7662. |
| [16] | ZHANG F, HUANG W, SHENG M, et al. MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients[J]. Tumour Biol, 2015, 6(3):2041-2048. |
| [17] | ZHANG T, SUN Q, LIU T, et al. MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14)[J]. Tumour Biol, 2014, 35(12):12593-12599. |
| [18] | MAZAN-MAMCZARZ K, GARTENHAUS RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)[J]. Leuk Res, 2013, 37(11):1420-1428 |
| [19] | JARDIN F, FIGEAC M. MicroRNAs in lymphoma, from diagnosis to targeted therapy[J]. Curr Opin Oncol, 2013, 25(5):480-486. |
| [20] | TAGAWA H, IKEDA S, SAWADA K. Role of microRNA in the pathogenesis of malignant lymphoma[J]. Cancer Sci, 2013, 104(7):801-809. |
| [21] | LOPOTOVA T, ZACKOVA M, KLAMOVA H, et al. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?[J]. Leuk Res, 2011, 35(7): 974-977. |
| [22] | LIU C, IQBAL J, TERUYA-FELDSTEIN J, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma[J]. Blood, 2013, 122(12):2083-2092. |
| [23] | 谢海涛. 结肠癌组织中miR-451表达的检测与分析[J]. 中南医学科学杂志, 2012, 40(3):257-259. |
| [24] | CHEN W, WANG H, CHEN H, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population[J]. Eur J Haematol, 2014, 92(5):407-412. |
| [25] | JU X, LI D, SHI Q, et al. Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia[J]. Pediatr Hematol Oncol, 2009, 26(1):1-10. |
| [26] | ZEN K, ZHANG CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev, 2012, 32(2):326-348. |
| [27] | FANG C, ZHU DX, DONG HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma[J]. Ann Hematol, 2012, 91(4):553-559. |
